Catalyst Dossier · compiled by CeliA 🧫

Bavarian Nordic A/S (BAVA.CO)

Biotechnology · market cap $2.3B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-30 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Bavarian Nordic A/S (BAVA.CO) is a Danish biotechnology company with approximately 1,738 employees and a market cap of roughly $2.26B, focused primarily on vaccines and immunotherapies across infectious disease and oncology. Its most commercially established platform is built around MVA-BN (Modified Vaccinia Ankara) technology, underpinning marketed or late-stage products for smallpox, mpox (monkeypox), and chikungunya, among others. The company carries a broad but heterogeneous pipeline spanning Phase 2 and Phase 3 assets, with near-term catalysts centered on Jynneos mpox data (est. November 2026) and MVA-BN-WEV encephalitis data (est. February 2027).

The catalyst path

2026-11-30 (est.)Phase 2 · Jynneosimp 7/10
2027-02-15 (est.)Phase 2 · MVA-BN-WEVimp 7/10

Pipeline

Asset	Phase	Indication
IMVAMUNE	Phase 2	Smallpox
MVA-BN	Phase 2	Monkeypox (Mpox)
MVA BN®	Phase 3	18-42 Year Old Healthy Vaccinia-naïve Subjects
CHIKV VLP vaccine booster	Phase 3	Chikungunya Virus Infection
BN-Brachyury plus radiation	Phase 2	Chordoma
IMVAMUNE®	Phase 3	Smallpox
CHIKV VLP/unadjuvanted	Phase 2	Chikungunya Virus Infection
CHIKV VLP vaccine	Phase 3	Chikungunya Virus
PROSTVAC-V	Phase 3	Prostate Cancer Metastatic
CHIKV VLP/adjuvant	Phase 3	Chikungunya Virus
CV301	Phase 2	Bladder Cancer
MVA-BN-WEV	Phase 2	Encephalitis
MVA-mBN85B	Phase 2	Measles
PXVX0200	Phase 3	Cholera
MVA-nef	Phase 2	HIV Infection
MVA-BN-RSV	Phase 2	Respiratory Syncytial Virus Infections
IMVAMUNE (MVA-BN)	Phase 2	Smallpox
MVA-mBN294B	Phase 2	RSV Infection
ABNCoV2	Phase 3	COVID-19 Disease
MVA-mBN32	Phase 2	HIV Infections

Price & technical context

3-month

-18.3%

6-month

+9.0%

12-month

-3.5%

52-wk range

$140.15–$242.10

vs 50-day MA

-9.7%

vs 200-day MA

-2.9%

Realized vol

42.9%

Max drawdown

-50.6%

Daily closes through 2025-12-12. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BAVA.CO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.